{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:35:44Z","timestamp":1790472944157,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.euroneuro.2013.01.003","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T16:32:38Z","timestamp":1361291558000},"page":"1636-1644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment"],"prefix":"10.1016","volume":"23","author":[{"given":"Louise","family":"Karlsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Ahlner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik C.","family":"Kugelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.01.003_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/bdd.753","article-title":"Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine","volume":"32","author":"Bachmeier","year":"2011","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0278-5846(98)00009-8","article-title":"Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages","volume":"22","author":"Bourin","year":"1998","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0924-977X(01)00101-8","article-title":"Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram","volume":"11","author":"Br\u00f8sen","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1124\/dmd.111.043083","article-title":"Species comparison of in vivo P-glycoprotein mediated brain efflux using mdr1a deficient rats and mice","volume":"40","author":"Bundgaard","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.v63n0410","article-title":"Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients","volume":"63","author":"Burke","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00007691-200112000-00011","article-title":"Enantioselective analysis of citalopram and metabolites in adolescents","volume":"23","author":"Carlsson","year":"2001","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/17425251003789394","article-title":"The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution","volume":"6","author":"Choong","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","article-title":"Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites","volume":"86","author":"Cordon-Cardo","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-005-0166-5","article-title":"Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test","volume":"183","author":"Crowley","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib10","doi-asserted-by":"crossref","first-page":"8186","DOI":"10.1073\/pnas.0401080101","article-title":"Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors","volume":"101","author":"Cryan","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib11","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/MCB.10.4.1652","article-title":"Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities","volume":"10","author":"Devault","year":"1990","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/dmd.104.001230","article-title":"The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A\/1B knockout mouse model","volume":"33","author":"Doran","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00406-006-0664-4","article-title":"ABC drug transporter at the blood\u2013brain barrier: effects on drug metabolism and drug response","volume":"256","author":"Ebinger","year":"2006","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hup.820","article-title":"Venlafaxine induces P-glycoprotein in human Caco-2 cells","volume":"22","author":"Ehret","year":"2007","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1515\/DMDI.2007.22.2-3.113","article-title":"A review on the relation between the brain-serum concentration ratio of drugs and the influence of P-glycoprotein","volume":"22","author":"Ejsing","year":"2007","journal-title":"Drug Metabol. Drug Interact."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejps.2005.11.002","article-title":"The role of transporters in drug interactions","volume":"27","author":"Endres","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejphar.2009.10.007","article-title":"Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram","volume":"626","author":"Fudio","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1124\/mol.62.6.1288","article-title":"Characterization of two pharmacophores on the multidrug transporter P-glycoprotein","volume":"62","author":"Garrigues","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1055\/s-2006-931585","article-title":"Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?","volume":"72","author":"Gutmann","year":"2006","journal-title":"Planta Med."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib20","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01244820","article-title":"The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer","volume":"88","author":"Hyttel","year":"1992","journal-title":"J. Neural Transm. Gen. Sect."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00213-010-2148-5","article-title":"Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model","volume":"215","author":"Karlsson","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.euroneuro.2010.04.004","article-title":"Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein","volume":"20","author":"Karlsson","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans","volume":"70","author":"Kim","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbr.2007.11.009","article-title":"Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice","volume":"188","author":"Kirschbaum","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0924-977X(00)00128-0","article-title":"In vitro metabolism of citalopram by monoamine oxidase B in human blood","volume":"11","author":"Kosel","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib27","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/sj.bjp.0704015","article-title":"In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats","volume":"132","author":"Kugelberg","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/chir.10266","article-title":"Stereoselective single-dose kinetics of citalopram and its metabolites in rats","volume":"15","author":"Kugelberg","year":"2003","journal-title":"Chirality"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00004850-200405000-00005","article-title":"Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder","volume":"19","author":"Lepola","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.euroneuro.2007.06.003","article-title":"A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs","volume":"18","author":"Linnet","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","article-title":"Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases","volume":"76","author":"Loscher","year":"2005","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S1461145705006462","article-title":"Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies","volume":"10","author":"Mansari","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib33","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1172\/JCI119784","article-title":"Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833","volume":"100","author":"Mayer","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib34","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/WNR.0b013e3282f04047","article-title":"R-citalopram prevents the neuronal adaptive changes induced by escitalopram","volume":"18","author":"Mnie-Filali","year":"2007","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1034\/j.1600-0773.2001.d01-118.x","article-title":"Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model","volume":"88","author":"Montgomery","year":"2001","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0028-3908(03)00138-2","article-title":"The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats","volume":"45","author":"Mork","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib37","doi-asserted-by":"crossref","first-page":"C440","DOI":"10.1152\/ajpcell.00491.2007","article-title":"Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood\u2013brain barrier","volume":"295","author":"Narang","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1476-5381.2011.01557.x","article-title":"Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings","volume":"165","author":"O\u2019Brien","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000028333","article-title":"Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes","volume":"59","author":"Olesen","year":"1999","journal-title":"Pharmacology"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","article-title":"Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine","volume":"50","author":"Owens","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/00498250310001630215","article-title":"Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats","volume":"34","author":"Perloff","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00007691-200304000-00007","article-title":"Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992\u20131997","volume":"25","author":"Reis","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00007691-199506000-00011","article-title":"Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography","volume":"17","author":"Rochat","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-8993(99)01461-4","article-title":"Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium","volume":"831","author":"Rochat","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0006-2952(98)00008-2","article-title":"Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver","volume":"56","author":"Rochat","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","article-title":"Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities","volume":"167","author":"Sanchez","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00213-004-1865-z","article-title":"Escitalopram versus citalopram: the surprising role of the R-enantiomer","volume":"174","author":"Sanchez","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib48","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0091-3057(03)00165-5","article-title":"R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety","volume":"75","author":"Sanchez","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib49","first-page":"465","article-title":"R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model","volume":"14","author":"Sanchez","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pbb.2003.12.001","article-title":"R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram","volume":"77","author":"Sanchez","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib51","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/37.2.2463300","article-title":"Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein","volume":"37","author":"Thiebaut","year":"1989","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-3956(03)00022-0","article-title":"abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice","volume":"37","author":"Uhr","year":"2003","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib54","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0006-3223(03)00074-X","article-title":"Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption","volume":"54","author":"Uhr","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jpsychires.2005.10.005","article-title":"Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls","volume":"41","author":"Uhr","year":"2007","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib56","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0893-133X(99)00095-0","article-title":"Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood\u2013brain barrier deficiency due to mdr1a P-glycoprotein gene disruption","volume":"22","author":"Uhr","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2007.11.017","article-title":"Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression","volume":"57","author":"Uhr","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2013.01.003_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","article-title":"Escitalopram 10mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"17","author":"Wade","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":"The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein","volume":"7","author":"Wang","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib60","first-page":"327","article-title":"Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats","volume":"22","author":"Wikell","year":"1999","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.003_bib61","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.jcp.0000227355.54074.14","article-title":"Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients","volume":"26","author":"Yin","year":"2006","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T15:02:11Z","timestamp":1539874931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0924977X13000199"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.01.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}